Available IPD datapackage for study 'An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes'

Primary Objective:

The primary objective of this study is to assess the overall safety of lixisenatide once
daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in
patients with type 2 diabetes in Japan.

Secondary Objective:

To assess the effects of lixisenatide in combination with background oral antidiabetic drug
(OAD) on:

- HbA1c;

- Fasting plasma glucose;

- Body weight.